Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial

NCT03363035 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.

NCT NCT03363035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial
Lead sponsor
Second Xiangya Hospital of Central South University
Phase
Phase 4
Overall status
Completed
Start date
January 15, 2018
Completion date
November 30, 2021
Enrollment
2,055 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, myocardial infarction, myocardial ischemia, unstable angina